Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology

30-04-2024 | Erectile Dysfunction | Urology – Original Paper

Which is better to predict erectile dysfunction and male sexual function in the context of metabolic syndrome: triglyceride–glucose index or visceral adiposity index?: a retrospective cross-sectional study

Authors: Mustafa Suat Bolat, Ipek Akalin Bolat, Cihad Dündar, Ramazan Asci

Published in: International Urology and Nephrology

Login to get access

Abstract

Purpose

Many factors influence male sexual function, including metabolic disorders such as metabolic syndrome (MetS). We aimed to investigate the effects of two metabolic indices, the triglyceride-glucose (TyG) index and the visceral adiposity index (VAI), on male sexual function.

Methods

A total of 400 men having sexual dysfunction were included. Anthropological data, comorbidities were recorded. Serum total testosterone, prolactin, and estradiol levels were recorded. Sex-specific VAI was calculated using the [(WC/39.68) + (1.88xMI)] × (TG/1.03) × (1.31/HDL) formula and using Ln (fasting triglycerides) × (fasting glucose)/2] formula, TyG index was calculated. Turkish-validated 15-item long-form of the International Index of Erectile Dysfunction (IIEF) questionnaire and male sexual health questionnaire (MSHQ) were used for erectile function and ejaculatory function, respectively. The ROC analysis was used to evaluate the predictive abilities of TyG and VAI cut-off values for ED risk.

Results

A higher TyG index and VAI were associated with an increased risk of ED. The presence of MetS further worsened sexual function, with lower scores in sexual satisfaction, orgasm, desire, and general satisfaction. The TyG index and VAI showed similar predictive abilities for ED. Patients with MetS had worse ejaculation quality compared to those without MetS.

Conclusions

These findings highlight the potential of the TyG index and VAI as convenient tools for predicting and assessing sexual dysfunction in men, particularly in the context of metabolic disorders. Early detection and intervention for metabolic syndrome and insulin resistance may help to mitigate their negative impact on male sexual function.
Literature
1.
Glina S, Sharlip ID, Hellstrom WJ (2013) Modifying risk factors to prevent and treat erectile dysfunction. J Sex Med 10(1):115–119CrossRefPubMed
2.
Salonia A, Bettochi C, Carvalho J, et al.(2020) EAU Guidelines on sexual and reproductive health 2020. In: European association of urology guidelines. 2020 Edition, European association of urology guidelines office, Arnhem, The Netherlands
3.
Corona G, Cipriani S, Rastrelli G, Sforza A, Mannucci E, Maggi M (2016) High triglycerides predicts arteriogenic erectile dysfunction and major adverse cardiovascular events in subjects with sexual dysfunction. J Sex Med 13(9):1347–1358CrossRefPubMed
4.
Lao XQ, Ma WJ, Sobko T et al (2015) Overall obesity is leveling-off while abdominal obesity continues to rise in a chinese population experiencing rapid economic development: analysis of serial cross-sectional health survey data 2002–2010. Int J Obes 39(2):288–294CrossRef
5.
Bolat MS, Kocamanoglu F, Ozbek ML, Buyukalpelli R, Asci R (2020) Can high visceral adiposity index be a risk factor for sexual dysfunction in sexually active men? J Sex Med 17(10):1926–1933CrossRefPubMed
6.
Terentes-Printzios D, Ioakeimidis N, Rokkas K et al (2022) Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nat Rev Cardiol 19:59–74CrossRefPubMed
7.
Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120(16):1640–1645CrossRefPubMed
8.
9.
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F (2008) The product of fasting glucose and triglycerides as a surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 6(4):299–304CrossRefPubMed
10.
Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M et al (2010) Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920–922CrossRefPubMedPubMedCentral
11.
Thomas GN, Ho SY, Janus ED, Lam KS, Hedley AJ, Lam TH (2005) Hong kong cardiovascular risk factor prevalence study steering committee. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population Diabetes Res Clin Pract 67(3):251–257
12.
13.
Beck AT, Ward C, Mendelson M (1961) Beck depression inventory (BDI). Arch Gen Psychiatry 4:561–571CrossRefPubMed
14.
15.
Nolan PB, Carrick-Ranson G, Stinear JW, Reading SA, Dalleck LC (2017) Prevalence of metabolic syndrome and metabolic syndrome components in young adults: a pooled analysis. Prev Med Rep 7:211–215CrossRefPubMedPubMedCentral
16.
Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuniga FA (2018) Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 17:122CrossRefPubMedPubMedCentral
17.
18.
19.
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed
20.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
21.
Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez-Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SO et al (2010) The product of triglycerides and glucose, a simple measure of insulin sensitivity. comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab 95:3347–3351CrossRefPubMed
22.
Zhang M, Wang B, Liu Y, Sun X, Luo X, Wang C et al (2017) Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride glucose index in normal-weight people: the rural chinese cohort study. Cardiovasc Diabetol 16:30CrossRefPubMedPubMedCentral
23.
Fritz J, Bjorge T, Nagel G, Manjer J, Engeland A, Haggstrom C et al (2020) The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers. Int J Epidemiol 49:193–204CrossRefPubMed
24.
Belladelli F, Boeri L, Pozzi E, Fallara G, Corsini C, Candela L, Cazzaniga W, Cignoli D, Pagliardini L, D’Arma A, Capogrosso P, Ventimiglia E, Montorsi F, Salonia A (2022) Triglycerides/glucose index is associated with sperm parameters and sperm dna fragmentation in primary infertile men: a cross-sectional study. Metabolites 12(2):143CrossRefPubMedPubMedCentral
25.
Yilmaz M, Karaaslan M, Tonyali S, Celik M, Toprak T, Odabas O (2021) Triglyceride-Glucose Index (TyG) is associated with erectile dysfunction: a cross-sectional study. Andrology 9(1):2047–2927CrossRef
26.
Maio MT, Hannan JL, Komolova M, Adams MA (2012) The caloric restriction prevents visceral adipose tissue accumulation and maintains erectile function in ageing rats. J Sex Med 9(9):2273–2283CrossRefPubMed
27.
Akdemir AO, Karabakan M, Aktas BK, Bozkurt A, Ozgur EG, Akdogan N et al (2019) Visceral adiposity index is useful for evaluating obesity effect on erectile dysfunction. Andrologia 51(6):e13282CrossRefPubMed
28.
Bolat MS, Ozbek ML, Şahin B, Yılmaz M, Kocamanoglu F, Buyukalpelli R et al (2021) Impact of high visceral adiposity index associated with metabolic syndrome on erectile function in sexually active men: results of a cross-sectional study. Int J Clin Pract 75(6):e14111CrossRefPubMed
29.
Dursun M, Besiroglu H, Cakir SS et al (2018) Increased visceral adiposity index associated with sexual dysfunction in men. Aging Male 21:187–192CrossRefPubMed
30.
31.
Morelli A, Corona G, Filippi S et al (2007) Which patients with sexual dysfunction are suitable for testosterone replacement therapy? j endocrinol invest. 2007;30: 880–888. ve yassin aa, saad f. improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 4:497–501
32.
Mancina R, Filippi S, Marini M et al (2005) Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum Reprod 11:107–115CrossRefPubMed
33.
34.
Poggiogalle E, Di Lazzaro L, Pinto A et al (2014) Health-related quality of life and quality of sexual life in obese subjects. Int J Endocrinol 2014:1–7CrossRef
Metadata
Title
Which is better to predict erectile dysfunction and male sexual function in the context of metabolic syndrome: triglyceride–glucose index or visceral adiposity index?: a retrospective cross-sectional study
Authors
Mustafa Suat Bolat
Ipek Akalin Bolat
Cihad Dündar
Ramazan Asci
Publication date
30-04-2024
Publisher
Springer Netherlands
Published in
International Urology and Nephrology
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-024-04057-x
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits